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Mental health problems constitute a significant part of pri-
mary care consultations.1 Optimal treatment of mental ill-
ness focuses on both symptom and functional recovery with 
a range of pharmacological, psychosocial and psychological 
interventions available.2 The appropriate use of medication 
is an integral part of effective management; however, medi-
cines are often used sub-optimally.3–10 Medication adherence 
for these enduring conditions is an on-going concern.11–13 To 
achieve better medicines-related outcomes for people 
affected by mental illness, health professionals need to pro-
vide collaborative and integrated care that involves the wider 
primary care team and supports the recovery process.14–18
In Australia, the majority of medications for mental health 
conditions are prescribed by general practitioners (GPs) and 
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dispensed by community pharmacists. As a result, commu-
nity pharmacists are encountering medicines-related prob-
lems (MRPs) associated with mental health on a daily basis.19 
Pharmacies are a health-care hub and pharmacists are in a 
strong position to assist mental health consumers with high 
prevalence conditions such as anxiety and depression.20 (In 
this article, mental health consumers refer to people who 
have a lived experience of a mental illness such as depres-
sion or anxiety. They may be viewed as health consumers in 
other contexts as comorbidity with other physical health con-
ditions is not uncommon. This terminology was applied fol-
lowing consultation with consumers, caregivers and 
advocates with considerable experience with mental health 
services.) Pharmacists’ skills and experience can be applied 
within their scope of safe and appropriate use of medicines 
to improve the quality use of these medicines for consumers 
with mental illness.19 Despite this, the literature is sparse, 
and compared with other chronic diseases, there is a dearth 
of information which evaluates models of medication man-
agement for mental health consumers within community 
pharmacy. This is surprising as there have been several 
reviews published outlining the impact of community phar-
macy–based disease state or medicines management services 
in areas other than mental health.16,21,22
This review set out to investigate the literature pertaining 
to mental health services delivered by community pharmacy. 
This article explores the role of community pharmacy in sup-
porting mental health consumers (and carers) to address 
MRPs. The focus is on both individual- and organisational-
level change within community pharmacies. This article out-
lines a conceptual schema, which helps to describe the 
literature from a range of concepts which together provide 
evidence for the best way to progress with service develop-
ment and evaluation. In the simplest terms, a conceptual 
schema is a platform for making sense of multiple streams of 
literature. This literature is made sense of through narrative 
analysis across areas outlined in the schema, rather than a 
systematic literature review which outlines individual stud-
ies as findings. The aim of this article is to draw together a 
range of literatures that help the development, implementa-
tion and evaluation of a medication support service focussed 
on mental health. Medication management support could 
include but is not limited to symptom management (control 
of anxiety and pain), support for lifestyle change (diet and 
exercise), improving adherence (having a routine and a 
plan), medicines management plan (reducing particular 
MRP), better information (understanding illness and medi-
cines) and improving sleep hygiene.
As part of the implementation of the service, approxi-
mately 500 mental health consumers with anxiety and 
depressive disorders will be invited to receive care from 100 
pharmacies across Australia, to help overcome challenges 
faced with their medication. This article reports the develop-
ment phase. The outcomes of the service implementation are 
forthcoming.
In order to build, implement and evaluate a service model 
for medication management for mental health consumers 
visiting community pharmacy, there is a need to understand 
what has previously ‘worked’ and/or ‘not worked’. This 
understanding needs to draw on the experience from chronic 
disease programmes and conditions with stigma. This article 
is a scoping review of the literature which is guided by a 
conceptual schema. The framework is broad; it is not a the-
ory, but a conceptual schema which draws together ideas and 
provides the ingredients for service design23 – in this case for 
community pharmacy. Therefore, this article presents the 
schema that will direct the design, implementation and eval-
uation of the proposed mental health intervention at the level 
of individual staff members as well as the community phar-
macy organisation as a whole.
Mental health–related problems pose a serious issue for 
primary care and the appropriate use of medication is an 
integral part of effective management. However, medicines 
are often used sub-optimally and community pharmacy 
could make a significant contribution to mental health con-
sumers, but there is a dearth of information about how this 
might best be done. This article shifts the focus of the current 
literature from medicines adherence; expanding beyond this 
to include other aspects of MRPs and posits a conceptual 
framework and recommendations for development and eval-
uation of a professional service. This process includes con-
siderations of organisational aspects and change management 
strategies, which was not part of the aim of previous 
studies.
Methodology and methods
This is not a systematic review about a single research ques-
tion but a scoping review which looks to relevant literature 
to be reported on and applied.24,25 In a sense this is precursor 
work to inform the development of a service that is informed 
on evidence from the literature. This work therefore repre-
sents translational (into practice) research rather than an 
empiric work stream. Therefore, this article presents a con-
ceptual schema which has informed the development of a 
community pharmacy service with a focus on clients who 
have MRPs associated with issues of mental health. In this 
way, the research explores different topic areas and has a dif-
ferent set of questions for the component parts; each contrib-
uting to the service design and implementation as a whole. 
The analytic process involves literature synthesis and inter-
pretation so that key issues emerge.26
Conceptual schema
The reason for the schema development is twofold. First, that it 
provides a framework in which to explore narrative around the 
important aspects of service implementation. This literature 
does not appear ‘in a single place’ and to date it has not been 
brought together in one place. Pharmacy practice researchers 
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have been relatively naïve in applying organisational level 
approaches to service development despite this being standard 
process outside of the community pharmacy sector. Second, 
the schema was used to develop and orient the whole service. 
Based on the schema the service was developed, staff were 
trained and the service was implemented and evaluated at mul-
tiple levels (forthcoming).
Potentially, the schema could cover a vast and diverse lit-
erature. However, a practical service design needs to be 
developed, implemented and evaluated. As a result, the 
review will be focussed and contained while providing depth 
within four components of particular relevance to the service 
(Figure 1). These components are broad in nature so that the 
scope of the review provides depth and breadth, and there is 
some overlap and linking between them which is addressed 
throughout. The schema provided a guide for the search such 
that the intervention could be contextualised within local and 
international literature, as well as policy.27
Systematic approaches will be taken to apply search terms 
within each of the four components of the broader concep-
tual frame, so that depth and breadth will be achieved in 
accordance with the questions needing to be answered. The 
analytic process will go beyond description of individual 
studies to a level of synthesis and interpretation to expose 
higher level findings from the detail of the individual study 
groupings.26
Components of literature search
Search terms. The following terms were applied to the vari-
ous components of the search: community pharmacy, com-
munity pharmacist AND mental health, interventions, 
services, service provision, medicines management, adher-
ence, concordance, assessment and skills, attitudes, beliefs, 
stigma, self-efficacy, collaboration, change, change manage-
ment, practice change, barriers, facilitators, organisational 
change, organisational change, organisational culture, 
organisational culture, programme evaluation, service evalu-
ation, intervention evaluation, programme effectiveness, ser-
vice effectiveness, intervention effectiveness, implementation 
evaluation, and quality of service.
Databases/search tools. This literature review spans the fields 
of pharmacy practice research, health services research, and 
organisational and business management theory. Based on 
this, different databases were utilised for different aspects of 
the search. An electronic search was conducted to identify 
current literature relating to each of the four components of 
the schema. Databases included MEDLINE, CINAHL, Pro-
Quest, Emerald, PsycINFO, ScienceDirect, PubMed, Web of 
Knowledge and International Pharmaceutical Abstracts 
(IPA). In addition, The Cochrane Library, Pharmacy Guild of 






















Figure 1. Conceptual schema.
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Australian government health websites were searched. 
GoogleScholar was the ‘lay’ search engine utilised, but only 
after academic search engines were exhausted. University 
libraries were searched in order to access doctoral theses rel-
evant to this area.
Analysis and interpretation. Only full original papers pub-
lished in peer review journals were included when assessing 
studies. A search of literature within each component of the 
conceptual schema was undertaken and the titles and 
abstracts of relevant papers reviewed. Those deemed appro-
priate from their abstracts were read in full. The approach to 
analysis, interpretation, and summary of the findings within 
each component was robust, yet subtly different for each. 
This is not a systematic review based on a single research 
question (see Table 1) but an amalgam of components each 
of which covers a different topic area and a different set of 
questions; each contributing to the programme as a whole.
Component 1. Analysis involved assessing systematic 
reviews and meta-analyses to determine the structures, pro-
cesses and outcomes of mental health randomised controlled 
trials (RCTs) in community pharmacy.28 Studies discovered 
through searching that were not included in the systematic 
reviews were added. In addition to making sense of ‘what 
did and did not work’, a synthesis of the literature as a whole 
was undertaken in order to describe the focus/elements of the 
whole body of work in this topic area, for example, country 
and culture and lack of focus on collaboration.26,27,29
Component 2. Analysis for this component required 
thought around the broader facets of medication management 
and identification of MRPs other than adherence. Alignment 
with government policy, funded programmes, and profes-
sional practice guidelines were reviewed and application to 
this project considered. Collaboration was deemed to be a 
significant theme within this project and for the interven-
tion and so tabulation of Australian medicines management 
programmes requiring significant collaboration (outside of 
mental health) was reviewed to provide an understanding of 
how that might work (facilitators) and/or the barriers to col-
laboration.
Component 3. Component 3 involved review of journal 
articles and standard management textbooks on organisa-
tional change.30,31 This is a broader and more wide ranging 
topic and both system and human factors were addressed. 
The literature was brought together at two levels – the indi-
vidual practitioner and the ‘whole of organisation’. Models 
used in pharmacy were considered, together with potential 
change tools from the management literature not previously 
applied in the pharmacy practice context. A synthesis of the 
facilitators and barriers to the implementation of clinical ser-
vices in community pharmacy was generated; mostly from 
Australasian literature. This was considered appropriate due 
to the context of the study and the significant focus on, and 
requirement of, change as part of this intervention.
Component 4. Analysis of the findings for Component 4 
followed a similar process to Component 3, in that literature 
from both pharmacy practice and management science was 
reviewed. This included peer-reviewed journals, books and 
doctoral theses. In addition to community pharmacy–based 
mental health studies, the evaluation of medicines manage-
ment programmes in other disease states was reviewed. A 
synthesis of the approaches taken to evaluation was con-
ducted by tabulating the studies and then grouping the evalu-
ative processes into like categories for interpretation.26,27,29
Findings: Literature synthesis and 
recommendations
Component 1 – community pharmacy–based 
mental health RCTs
This component explores controlled studies in the area of 
mental health within community pharmacy in order to 
better understand what ‘has worked’ in this context and 
the gaps in the literature that required addressing through 
service design.
Blalock et al.16 suggest many studies demonstrate bene-
fits of pharmacist-provided services on patient health, but 
that evidence is limited for the community pharmacy setting. 
Four systematic reviews of pharmacy interventions for 
improving medicines use in mental health consumers con-
ducted between 2005 and 2012, largely focussed on impact 
on medication adherence and depressive symptoms. The 
majority of studies are in-patient32 or clinical pharmacy ser-
vices.15,17 Scarcity of literature on services delivered in com-
munity pharmacies is surprising given the prevalence of 
mental illness and its impact.1,33
Chong et al.17 reviewed 26 studies mainly in primary care 
and only 3 of 22 studies reported by Bell et al.15 pertained to 
community pharmacy. Two later reviews35,36 identified addi-
tional community pharmacy studies, associating improved 
antidepressant adherence with pharmacist intervention.35,37–39 
However, authors cautioned that data are limited35 and did not 
differentiate service models.36 Two RCTs added through this 
review, focussed on patients initiated on antidepressants,40 
and a pilot of community pharmacist and key worker home 
visits to older adults with mental health problems.41
Evidence of pharmacist intervention improving medication 
adherence and consumer outcomes is predominantly from the 
Netherlands and the United States and outside of community 
pharmacies. Reflection on whether interventions align with 
Australian community pharmacy is warranted42 and the impact 
of community pharmacy interventions needs exploration.
What does and does not work for consumer interventions in 
mental health. Complex, multifaceted interventions more 
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effectively improved adherence to antidepressants than 
information transfer (education) alone.17 Disentangling the 
influence of different interventions on various outcomes is 
challenging. The majority of interventions emphasise educa-
tional aspects over behavioural strategies.36 Neto et al.43 sug-
gest that simply advising patients to take medication as 
recommended is less helpful and could lead to medication-
related reactance. Brehm’s44 Theory of psychological reac-
tance proposes that when individuals perceive that their 
freedom to select ‘when and how’ to conduct their behaviour 
is restricted, individuals tend to re-assert freedom of choice 
and act in the opposite fashion. Shared decision-making 
between pharmacists and patients could limit this,45 and 
Neto et al.43 proposed strategies used to elicit reduction of 
risky behaviours for promoting adherence. Incorporating 
these concepts in interventions will support pharmacists to 
identify and counter medication-related reactance. These 
strategies also reflect aspects of the four domains of patient-
centred care; individualised, respectful, holistic and empow-
ering care identified as important to health service delivery 
by Morgan and Yoder.46
Chong et al.17 concluded that combining educational, 
behavioural, affective and provider-targeted strategies was 
more likely to improve adherence to antidepressants and 
therefore clinical outcomes. Examples include motivational 
interviewing and goal-setting with monitoring.17 Pharmacist 
coaching combined with multi-media education has varia-
ble impact on adherence and symptoms of depression or 
anxiety.38,47–49 Pharmacist monitoring was predictive of 
patient satisfaction and self-reported adherence when initi-
ating antidepressants,39 and telephone calls improved adher-
ence.50 A single RCT attributed improved adherence and 
reduced patient-reported MRP to home visits from trained 
community pharmacists and key workers.41 Interventions 
usually involved consumers commencing antidepressants 
and excluded other cohorts possibly requiring support.
Provider-targeted strategies such as feedback to the GP 
present in clinical pharmacy service models15,17,32 are miss-
ing from community pharmacy interventions. The literature 
supports the design of a comprehensive multifaceted service 
where patients are supported by multiple strategies, referred 
as necessary and health professionals are notified of patient 
progress in a collaborative fashion. Paradoxically, service 
design is expected to be simple, pragmatic, easily imple-
mented and not time consuming or onerous on pharmacists.
Recommendations for Component 1: mental 
health community pharmacy RCTs
A full synthesis of the literature for this component has been 
reported elsewhere (forthcoming) and the following recom-
mendations are made from the literature (Box 1).
Table 1. Components of literature search.
Component no. Search section Questions to answer
1. Community pharmacy 
interventions in mental health 
(structure, process outcome)
Where does the current evidence lie in mental health interventions?
Elements of intervention (structure), how delivered (process), 
outcomes achieved (outcomes)
2. Expanding medicines management 
beyond adherence
In addition to compliance, what other medicines-related problems 
need to be addressed?
Are there models other than Stowasser’s that warrant 
consideration?
What are the key components of a medication management service?
What can be learned from other areas of chronic disease 
management?
Interventions to meet consumer needs based on Stage 2 findings:
Role, relationships, stigma, knowledge, skills, attitudes
What can be learned from other pharmacy delivery models (i.e. 
clinical pharmacist in primary care)?
3. Change management – barriers/
facilitators
••  Individual practice change
••  Organisational change
Are there barriers and facilitators to service provision in community 
pharmacy that are specific to mental health initiatives?
What work has been published about organisational-level and 
individual practice–level change in community pharmacy?
How is the intervention going to support the potential need for 
change?
Working with others – what are the issues?
How does the intervention need to be designed to assist this?
4. Service evaluation
••  Implementation processes
••  Impact on participants
How does service evaluation literature apply to community 
pharmacy?
What aspects of the implementation process can be evaluated?
How can change in practice be evaluated?
How can the impact on staff be evaluated?
How can the impact on and outcomes for consumers be evaluated?
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Component 2 – expanding medicines 
management beyond adherence
This component represents the movement away from 
adherence as the only medicines-related problem (MRP) 
and the broadening of medicines management models 
involving multifaceted interventions, collaboration and 
alignment with funded clinical programmes.
Adherence has been defined as the extent to which a per-
son’s medication taking behaviour coincides with medical 
advice.51 Many studies focus on adherence as a key outcome, 
and this review expands the focus to reflect a myriad of other 
MRPs.52–56 There is evidence that improvement in clinical 
outcomes may not be mediated through adherence alone,17,32 
and that adherence strategies can be part of multifaceted inter-
ventions, making it difficult to demonstrate a causal link.21 
Challenges in obtaining robust measures of adherence further 
limit its value as a sole measure of success57 and adherence 
does not reflect the influence of external factors or the impor-
tance of inter-professional collaboration to patient outcomes.
Identifying other MRPs. International literature provides evidence 
of pharmacist detection and management of a range of MRPs,58 
through community pharmacy medication management pro-
grammes,59 pharmacy surveys,60 aggregate analysis of incidents 
involving psychotropics,61 medication error detection in 
pharmacy,62 and identifying preventable drug-related morbid-
ity.63,64 MRPs include inappropriate adherence, need for addi-
tional therapy, wrong drug, unnecessary therapy, adverse drug 
reaction, dose too low or too high and drug interactions.59,60
Australian literature exploring MRP beyond adherence 
focussed on identification/detection, classification, documen-
tation and management of MRP.52–56 Analysis of 6239 clinical 
interventions in Australian community pharmacies reported 
medication selection problems (30.8%) and educational issues 
(24.4%), most commonly, followed by incorrect doses (20.1%). 
Common MRP experienced by mental health consumers 
included potential adverse drug reactions, suspected adverse 
drug reactions, potential drug interactions and taking additional 
medicines unknown to the GP.65 Antidepressants were the most 
commonly prescribed nervous system agent, followed by anal-
gesics then antipsychotics.65
These findings highlight the importance of inter-professional 
collaboration to patient outcomes and MRP management.59,65 
Australasian literature explores integration of community 
pharmacists into primary health teams for medicines manage-
ment.66–76 Review of literature exploring collaborative medi-
cation review between pharmacists and GPs found decreased 
numbers, greater recognition and resolution of MRP; 
increased compliance and patient knowledge; and improved 
prescribing, quality-of-life scores, medication appropriate-
ness index scores, and clinical values.77 Most studies 
described positive outcomes on satisfaction for patients and 
health-care providers. Patient involvement was important for 
motivation to change and sustained intervention impact.
Interventions are multifaceted and complex. The type of 
intervention that results in the greatest and most sustained 
improvement is unknown.17,21 Interventions are often com-
plex, adherence does not always mediate outcomes and dis-
entangling cause and effect may be impossible. It makes 
sense to adopt complex multifaceted interventions that 
work ‘as a package’ and recognise management of chronic 
health conditions, and related treatment burden extends 
beyond medication adherence.78,79 Systematic reviews of 
the clinical services and cost-effectiveness of RCTs of 
community pharmacy services in 200322 and a decade 
later16 support this.
Adherence as a measure of intervention impact. No single 
method of assessing medication compliance or adherence 
was identified as completely valid and reliable in a literature 
review conducted during an adherence study.57 Direct meas-
urement is challenging, multiple methods are used and there 
is a predominance of indirect methods which lack robust evi-
dence and can be difficult to interpret.17 It is important to 
combine validated measures of adherence80–83 with other 
forms of evaluation.
Measuring adherence does not reflect the influence of 
external factors. Modifiable factors may include medication 
complexity, relationship between patient, pharmacist and pre-
scriber, health and medication beliefs, patients’ understanding 
and perception of illness and treatment, access to health-care 
providers, side-effects, and forgetting to take medications.
Mental health consumers participating in a medication 
support intervention will likely experience MRP reported 
above and benefit from complex, multifaceted interventions 
that extend medicines management beyond adherence. 
Multiple measures are needed to effectively evaluate the 
Box 1. Recommendations – design, engagement and evaluation.
Medication support intervention design:
••   The intervention should combine structured counselling, 
information provision and behaviour change strategies
••   Training should build skills that facilitate a concordant 
approach
••  Train pharmacists to look beyond adherence
••   Integrate collaboration with other health professionals, 
especially general practitioners
••  Define standard clinical practice
Consumer recruitment and engagement:
••   Expand and make explicit the consumer eligibility criteria 
beyond people initiating therapy (i.e. collecting a newly 
prescribed medication)
••   Define clear entry and exit points to the medication 
support intervention
••   Have processes that monitor consumer recruitment and 
identify slow adopters
••  Evaluation
••   Broaden the evaluation to include implementation 
process, change, and impact on all stakeholder groups
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impact and sustainability of these interventions. Interventions 
should incorporate measures that complement adherence, 
consider modifiable contextual factors and utilise and 
explore inter-professional collaboration.
Recommendations for Component 2: expanding 
medicines management beyond adherence
Recommendations in order to broaden the focus beyond 
adherence are outlined in Box 2.
Component 3 – change management: individual 
practice and organisational change
Widening the framework; implementing and evaluating 
change. The aim of most of the studies outlined in Compo-
nent 1 of this review was to assess effectiveness, not neces-
sarily implementation or change management of the services 
provided. This aspect has been identified as an important 
part of the service design, implementation and evaluation of 
an initiative for mental health clients in the community 
pharmacy context. Evaluation in the mental health studies 
outlined in Components 1 and 2 was focussed largely on 
consumer health outcomes (disease specific and quality of 
life) and adherence ratings using validated and accepted 
measures. However, the findings suggest a need to widen the 
evaluation to include consumers, pharmacists, pharmacy 
staff and other health professionals (see also Component 4).
Individual practitioner–level change. There are two aspects of 
change to consider at the individual level: change in attitude 
and technical change in practice. Readiness to change state-
ments correlate with actual behaviour and this needs to be used 
as a surrogate for actual change.84 There is Australasian litera-
ture addressing practice change in community pharmacy.85–93 
Local findings are important as change is contextually bound 
and management of change is impacted on by local environ-
mental factors.
An Australian study used the Stages of Change Model57 
to assess change for both pharmacists and consumers and to 
outline strategies for each stage: pre-contemplation, contem-
plation, preparation, action – maintenance and review. This 
appeared to be an adequate approach, at least for an adher-
ence-based initiative, but should be widened in this interven-
tion to include all MRPs that could be identified by 
community pharmacy and strategies to address them.18
Barriers and facilitators to implementing cognitive services. Aus-
tralasian studies have identified a series of barriers and facil-
itators to effective implementation of cognitive pharmacy 
services.87,89,92,93 Physical and human factors should be con-
sidered including pharmacy layout and interactions among 
pharmacy staff, customers and external stakeholders.89 Phar-
macist confidence has been a significant barrier to change 
and the implementation of enhanced clinical services in New 
Zealand93 and Canada94,95 and has been reported as a facilita-
tor for change in Australia.85 The importance of skills, 
knowledge, attitudes and beliefs of staff at all levels in deal-
ing with mental health consumers will be given due credit in 
the design.96–100 The concept of ‘self-efficacy’ is therefore 
important at the individual level and ‘whole of pharmacy 
level’.
Organisational change. There has been a focus on organisa-
tional-level change in pharmacy practice in Australasia.85 
Organisational-level change centres on systems and human 
factors. At the collective (all staff) level, this has been 
described as ‘organisational culture’.
The importance of organisational culture, the collective 
thought and action – the ways we think and act for the change 
process (both enabling and resisting) – is well recognised 
within the broader management literature.101–103 Beliefs and 
values drive attitudes to behaviour and practice which influ-
ence outcomes for individuals and organisations.103,104 It is 
an important concept that until recently has not been given 
sufficient attention by pharmacy practice researchers.42 This 
is surprising based on the fact that so much of what we do in 
Box 2. Recommendations to expand medication management 
beyond adherence.
Identify, document and address other MRPs as well as 
adherence
A synthesis from the literature suggests the following MRPs 
have relevance:
••   Unnecessary and inappropriate prescribing  
(over-prescribing)
••  Drug selection
••  Dosing – under and overdosing
••  Drug interactions
••  Complexity and the need for simplification
••  Under prescribing – untreated indications
••  Lack of therapeutic response
••  Lack of appropriate monitoring
••  Educational issues and cost barriers
Utilise standard approaches for identification and 
documentation of MRPs using current systems
Training that increases awareness and improves skills
Provide insight into consumer/carer experiences
••  Service that they value and which exceeds expectations
••   Desire for engagement and information  
(e.g. on side-effects)
••   Opportunities to support consumers through therapy 
change
Emphasise practical skill development in motivational 
interviewing
Provide consumer friendly resources and allow participants to 
revisit training as needed
Evaluate intervention impact
Incorporate measures beyond adherence (e.g. consumer 
perspectives on service quality)
MRPs: medicines-related problems.
 at Curtin University Library on May 23, 2016smo.sagepub.comDownloaded from 
8 SAGE Open Medicine
our organisations is influenced by the way staff collectively 
think and act and follow the tenet of: ‘the way we do things 
around here’. There are tools to assess the organisational cul-
ture pre- and post-intervention104,105 but critiquing each of 
the available tools (relative to pharmacy) needs to be under-
taken and this lies outside the scope of this article.
The Pharmacy Change Readiness Wheel (PCRW) has been 
designed for use in Australian community pharmacy. The 
PCRW depicts individual-level practice change, the readiness 
and management of organisational level change, and the over-
lap between the two. Custom-designed modules of training 
about the PCRW have been delivered (in the Australian con-
text) prior to the implementation of an asthma service.106 The 
PCRW includes questions of a business/management nature 
but also the need for change/change orientation. This system-
atic approach to management of practice change using theo-
retical concepts had not previously been undertaken in 
Australian community pharmacy.106 Importantly, pharmacists 
were unaware of the complexity of change as a concept and of 
effective change management strategies during this study. 
Education and training will attempt to ensure this is not an 
issue for the current intervention.
Collaboration. Compared with hospital pharmacy, there has 
been a lack of integration of community pharmacy into men-
tal health teams and within the primary care sector. This will 
require a significant degree of change at multiple levels 
including individual pharmacy staff (micro), community 
pharmacy as an organisation (meso), and at the environmen-
tal policy level (macro).92 A lack of sustainable and viable 
service models has not helped with the required 
change.19,87,89,93 However, in Australia, there are now sus-
tainable funding streams to align this type of activity with. 
Under the 5th Community Pharmacy Agreement (5CPA) the 
time has come to design and evaluate a mental health medi-
cines management model which aligns with funded clinical 
programmes.107
Recommendations for Component 3: change 
management
Training about change management and assessment of imple-
mentation processes at the organisational level is an integral 
part of the conceptual schema guiding this intervention. The 
project involves multi-level service change at micro (indi-
vidual) and meso (organisational) levels. The implementation 
process needs to address both levels and in fact this is one of 
the contributions of this article. Organisational-level assess-
ment needs to occur in addition to readiness and actual prac-
tice change of individual staff. This intervention is not ‘usual 
care’ and the implementation phase is likely to be more effec-
tive if lead pharmacists in participating community pharma-
cies are trained in change management, as it specifically 
relates to the intervention. There is strong linkage between 
the alignment outlined in the previous section and change 
management (Boxes 2 and 3). There are several change sche-
mas that could be applied from management science, but not 
all have been validated in the pharmacy setting.30,108 Most of 
these models are based on management and leadership prin-
ciples rather than change among clinical practitioners. As 
previously described, the PCRW is a pharmacy-specific 
model assessing individual practitioner and organisational-
level change.85
Component 4 – evaluative strategies
The literature review highlights the following issues which 
need to be considered as part of the evaluation planning.
A focus on adherence and health outcomes. The focus of eval-
uation in community pharmacy mental health RCTs was on 
health outcomes for consumers, degree of medicines adher-
ence, and broader assessments such as quality of life. The 
focus has been on medicines adherence assessed through 
consumer self-report, electronic pill count, and pharmacy 
records. This will need to be addressed in the intervention 
and an Australian study using the Stages of Change Model 
provides adequate direction and strategies with regard to 
medicines adherence.57 Data will need to be collected on 
other types of MRP identified and how they were addressed 
by the pharmacy.
Lack of evaluation of implementation process. The authors are 
not aware of any RCTs (at least in mental health delivered by 
community pharmacy) that evaluated the implementation 
process or the impact of programme implementation on 
pharmacists, other pharmacy staff, and different health-care 
providers.
Box 3. Recommendations for change management.
Implementation of intervention by community pharmacy:
••  Consider issues of alignment outlined in Component 3
••   Assess readiness to change in pharmacy and target 
pharmacies based on this
••   Assess current and preferred/required culture for 
improving effectiveness
••  Think about change management as a broad construct
••   Delineate the cross-over between individual practitioner 
change and organisational-level change
••   Adopt tools which help both planning and evaluation of 
change
••  Provide change management strategies
••  Anticipate and address barriers
Evaluation of intervention:
••   Extend evaluation beyond adherence and health  
outcomes
••   Consider consumer perspectives, pharmacists and 
pharmacy staff
••   Use validated tools where available or adapt to mental 
health context
••  Evaluate impact of implementation and related change
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A recent study has identified facilitators and barriers to 
implementing targeted medication adherence interventions in 
community pharmacy chains. The focus is on each individual 
pharmacy practice with the aim of describing adaptations of 
the targeted intervention and organisational structures. This 
qualitative work exposed five themes including all pharma-
cists’ need to understand the relationship of patient care pro-
grammes to their corporation’s vision; providing 
individualised, continual support and mentoring to pharma-
cists; anticipating barriers before implementation; encourag-
ing active patient engagement; and establishing best practices 
regarding implementation of patient care services.109
This intervention is expected to be broader than adher-
ence alone, and analysis of the medicines management liter-
ature for chronic disease demonstrates a large range of 
programmes and outcomes evaluated.
Pharmacist self-efficacy and readiness for change. Self-efficacy 
rating scales for pharmacists have been reported in commu-
nity pharmacy literature110–112 but have not been assessed in 
the case of mental health initiatives. An Australian study rec-
ommended applying the Stages of Change Model to assess 
readiness for change for pharmacists and their perceived 
importance of the need for change.57 This overlaps with the 
discussion in Component 3 – change management.
Stakeholder satisfaction is very important. There were few 
studies that assessed consumer satisfaction with service pro-
vision including their perception of pharmacy staff attitudes 
while delivering the service. There is literature supporting 
the use of consumer satisfaction ratings in community phar-
macy and these can be compared and contrasted with six 
simple questions asked in the National Compliance Trial 
(NCT) scale. If adopted, these scales will need to be amended 
to include a focus on pharmacist attitude towards mental 
health consumers.
Be cognisant of complexity. The evaluation needs to be care-
fully considered in line with findings from the Managing 
Mental Illness and Promoting and Sustaining Recovery 
(MMIP) project; the main issue being that the research pro-
cess made the ‘day to day’ pharmacy operations more com-
plicated. The MMIP study and its evaluation were perceived 
to be too complex by participants.18 The paradox is that a 
simple intervention is needed; one that is required to align 
with funding streams, integrated with other health profes-
sionals and stakeholders, comprehensive and multifaceted, 
and step past the simple act of information provision to elicit 
consumer behaviour change. The evaluation is expected to 
be equally comprehensive and so collected data need to be 
succinct yet informative.
Through broadening this intervention there is an expecta-
tion that a wider data set (than previously) will be collected. 
Box 4 outlines the evaluation of medicines management pro-
grammes outside of mental health which can be drawn upon.
Holistic approaches: multi-stakeholder assessment of service 
quality. Donabedian suggests that quality of health service 
provision and the outcomes gained are dependent on the 
structure and processes in place.28 Tools to measure quality 
of service provision are available for use in community phar-
macy and these are outlined in the recommendations.113,114 
Feasibility studies suggest that they are relatively fast (5–
8 min) and easy to complete which warrants consideration. 
There is, however, a scarcity of literature which evaluates the 
entire implementation process of medication management 
interventions and the impact on multiple stakeholders includ-
ing pharmacists and their staff, consumers, and other health-
care professionals, particularly GPs.
Recommendations for Component 4: evaluation 
tools
There are five domains to consider with respect to the tools 
for evaluation: the need to assess the implementation pro-
cess, the change in organisational culture required, under-
standing mental health consumer satisfaction, determining 
pharmacy staff attitudes and levels of self-efficacy, and 
assessment of service quality. The merits of the various 
measurement tools need to be carefully considered (Table 2) 
in line with findings from the MMIP study; the main issue 
being that the research process made the ‘day to day’ phar-
macy operations more complicated.
There does not seem to be pre-validated tools available 
which evaluate the implementation process or the impact on 
staff, consumers and other health-care professionals from 
that viewpoint. Likewise, a mental health–specific consumer 
satisfaction survey validated in community pharmacy was 
not found. Table 2 outlines the tools available for consumer 
satisfaction ratings in community pharmacy. Assessing 
Box 4. Evaluation summary for non-mental health community 
pharmacy initiatives.
••   Multifaceted interventions with a focus on evaluation of 
health outcomes for consumers
••   A focus on adherence and outcomes with intervention 
effects that is difficult to ‘unpack’ and disentangle
••   Some studies include evaluation of pharmacist 
perceptions, readiness to engage, and individual 
performance
••   A minority of studies assess the experiences of other 
health providers and in particular GPs
••   In studies that assess general practice involvement there 
is the acknowledgement that key stakeholders (doctors 
and nurses) need to be more integrally involved in both 
design and implementation
••   Lack of conceptual schemas such as Stowasser’s model, 
that is, ‘the intervention’ is in the broadest sense ‘the 
model’
••   Pre- and post-implementation surveys have been 
undertaken
GPs: general practitioners.
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pharmacy staff attitudes, knowledge, skills, confidence and 
self-efficacy in dealing with mental health consumers is also 
critical. There are scales available to measure attitudes and 
self-efficacy particularly around implementation processes 
although these are not specific to mental health (Table 2). 
Change will need to be facilitated and assessed at the indi-
vidual practice level and whole of organisational change, 
based on levels of readiness and organisational culture. 
These tools are valid and reliable. Training around change 
management is advisable and will need to be assessed.
Our review found two instruments for assessing overall 
quality of service provision from community pharmacy 
(Table 2) which demonstrated excellent face and content 
validity and reliability. Feasibility studies suggest that they 
are relatively fast (5–8 min) and easy to complete which 
should facilitate their utility in practice.
Conclusion
This review set out to explore the literature pertaining to 
mental health services delivered by community pharmacy. 
The objectives are to develop and trial strategies that improve 
and assist people with mental illness to manage their medica-
tion requirements and to evaluate the effectiveness of the 
strategies in a naturalistic study setting.
A four-component conceptual framework guided the 
search. Component 1 outlines a review of the literature per-
taining to community pharmacy studies in mental health 
which were largely focussed on adherence and consumer 
health outcomes. Component 2 expanded the focus beyond 
adherence to medicines management and considered models 
from outside of mental health. It also addressed the identifi-
cation of MRP other than adherence, alignment with funded 
clinical programmes, and a greater focus on collaboration 
with other health-care providers. Component 3 centred on 
practice change at the individual level and whole of organi-
sation change. The barriers and facilitators to implementa-
tion from consumers, pharmacy staff and other health-care 
providers were reviewed. There was significant Australasian 
literature in this area to draw upon. Component 4 involved a 
search of the processes of evaluation utilised within medi-
cine management programmes and other services provided 
within the community pharmacy context and application for 
this intervention. A synthesis of this literature provides an 
understanding of the evaluation strategies and tools that 
could be adopted.
There is significant choice when thinking about the 
development and evaluation of an intervention of this nature 
and, with it, the potential for a high level of complexity. The 
literature suggests that multifaceted interventions that 
include behavioural strategies combined with information 
transfer are more effective than education alone. The chal-
lenge in the development of this intervention is treading the 
fine line between high engagement and simple interven-
tions, alongside the need to develop a naturalistic study 
involving multiple stakeholders. Likewise, there is a need to 
collect data not only on impact but also on the implementa-
tion process from multiple viewpoints. The recommenda-
tions from a literature review based on a structured 
conceptual schema provide the foundation for an interven-
tion to improve medicines-related outcomes for consumers 
with mental health problems.
Table 2. Evaluative tools.
Domain Tool Description References
Implementation process
 
Levels of collaboration will 
need to be assessed
Social network analysis Scahill;34 Roberts et al.;91 
Roberts et al.;90
Assessing readiness for 
change
Pharmacy Wheel of 
Change Model




20-item Competing Values 
Framework (CVF)






Likert-based Bultman and Svarstad;39 
Chong et al.;17
NCT study Six question Likert scale Feyer et al. (2012)57
MacKeigan–Larson 
Satisfaction Score (later 
revised as the Larson, Rovers, 
MacKeigan Score (LRMS))
The LRMS contains 20 
items
MacKeigan and Larson 
(1989)115; Larson et al. 
(2002)116; Larson and 
MacKeigan (1994)117
Satisfaction with Pharmacist 
Scale (SWPS)
The SWPS is considerably 
shorter than the LRMS
Hernández et al. (2000)
Pharmacy staff attitudes 
and self-efficacy 
Attitudes and self-efficacy 
scales
Individual scales Taylor et al.;10 Martin  
et al. 110
Implementation issues Zardaín et al. (2009)118; ; 
Morken et al.111
Overall service quality Halsall et al. (UK) and White 
and Klinner (AUS) scales
Holistic service provision 
scales
Halsall et al.113; White and 
Klinner114
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